Literature DB >> 28756934

Postoperative Anticholinergic Poisoning: Concealed Complications of a Commonly Used Medication.

Xiao Chi Zhang1, Natalija Farrell2, Thomas Haronian1, Jason Hack1.   

Abstract

BACKGROUND: Scopolamine is a potent anticholinergic compound used commonly for the prevention of postoperative nausea and vomiting. Scopolamine can cause atypical anticholinergic syndromes due to its prominent central antimuscarinic effects. CASE REPORT: A 47-year-old female presented to the emergency department (ED) 20 h after hospital discharge for a right-knee meniscectomy, with altered mental status (AMS) and dystonic extremity movements that began 12 h after her procedure. Her vital signs were normal and physical examination revealed mydriasis, visual hallucinations, hyperreflexia, and dystonic movements. Laboratory data, lumbar puncture, and computed tomography were unrevealing. The sustained AMS prompted a re-evaluation that revealed urinary overflow with 500 mL of retained urine discovered on ultrasound and a scopolamine patch hidden behind her ear. Her mental status improved shortly after patch removal and physostigmine, with complete resolution after 24 h with discharge diagnosis of scopolamine-induced anticholinergic toxicity. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Although therapeutically dosed scopolamine transdermal patches rarely cause complications, incomplete toxidromes can be insidiously common in polypharmacy settings. Providers should thoroughly evaluate the skin of intoxicated patients for additional adherent medications that may result in a delay in ED diagnosis and curative therapies. Our case, as well as rare case reports of therapeutic scopolamine-induced anticholinergic toxicity, demonstrates that peripheral anticholinergic effects, such as tachycardia, dry mucous membranes, and hyperpyrexia are often not present, and incremental doses of physostigmine may be required to reverse scopolamine's long duration of action. This further complicates identification of the anticholinergic toxidrome and diagnosis. Published by Elsevier Inc.

Entities:  

Keywords:  anticholinergic syndrome; emergency department; pharmacology; physostigmine; reversal; scopolamine; toxicology

Mesh:

Substances:

Year:  2017        PMID: 28756934     DOI: 10.1016/j.jemermed.2017.05.003

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  6 in total

1.  Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System.

Authors:  Stephen L Thornton; Micheal A Darracq
Journal:  J Med Toxicol       Date:  2019-08-13

2.  Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.

Authors:  Octavian Vasiliu
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

Review 3.  The Pharmacological Treatment of Pediatric Vertigo.

Authors:  Pasquale Viola; Gianmarco Marcianò; Alessandro Casarella; Davide Pisani; Alessia Astorina; Alfonso Scarpa; Elena Siccardi; Emanuele Basile; Giovambattista De Sarro; Luca Gallelli; Giuseppe Chiarella
Journal:  Children (Basel)       Date:  2022-04-20

Review 4.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 5.  Beauty of the beast: anticholinergic tropane alkaloids in therapeutics.

Authors:  Kyu Hwan Shim; Min Ju Kang; Niti Sharma; Seong Soo A An
Journal:  Nat Prod Bioprospect       Date:  2022-09-16

6.  Determination of Scopolamine Distribution in Plasma and Brain by LC-MS/MS in Rats.

Authors:  Juan Chen; Anjing Lu; Daopeng Tan; Qianru Zhang; Yanliu Lu; Lin Qin; Yuqi He
Journal:  Int J Anal Chem       Date:  2022-09-30       Impact factor: 1.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.